Key result
Electret-coated DES (e-DES) demonstrated the lowest area of stent surface covered by fibrinogen and platelets and the smallest average size of deposits compared to BMS and standard DES.
Why the study?
Efforts to reduce stent thrombosis by altering blood-stent interactions are longstanding, and the efficacy of electret coating technology to confer thrombo-resistant properties to stents was assessed.
Does electret coating on drug-eluting stents reduce thrombogenicity compared to standard DES and bare metal stents in an in vitro perfusion model?
Does electret coating on drug-eluting stents reduce thrombogenicity compared to standard DES and bare metal stents in an in vitro perfusion model?
Electret coating technology confers significant antithrombotic properties to drug-eluting stents in an in vitro model, suggesting a potential approach to reduce stent thrombosis.
Answers are grounded in this paper and cite their sources.
Electret-coated stents merit clinical trials for thrombosis prevention; leaves open whether benefits extend beyond in vitro models.
Stent thrombosis (ST) is a catastrophic event and efforts to reduce its incidence by altering blood-stent interactions are longstanding. A new electret coating technology that produces long-lasting negative charge on stent surface could make them intrinsically resistant to thrombosis. We assessed the thrombogenicity of stents using an annular perfusion model with confocal microscopy, and determined the efficacy of electret coating technology to confer thrombo-resistant properties to standard stents. Using an annular perfusion chamber, Bare Metal Stent (BMS), standard uncoated DES (DES), and Electret-coated DES (e-DES) were exposed to human blood under arterial flow conditions. Deposits of fibrinogen and platelets on the stent surface were analyzed using immunofluorescence staining and confocal microscopy. Surface coverage by fibrinogen and platelets and the deposit/aggregate size were quantified using computerized morphometric analysis. The experimental methodology produced consistent, quantifiable results. Area of stent surface covered by fibrinogen and platelets and the average size of the deposits/aggregates were lowest for e-DES and highest on BMS, with DES in the middle. The size of fibrinogen-deposits showed no differences between the stents. The testing methodology used in our study successfully demonstrated that electret coating confers significant antithrombotic property to DES stents. These findings warrant confirmation in a larger study.
No takes yet. Share an insight, caveat, or question.
Zafar et al. (2021) studied Stent thrombosis. Electret-coated DES (e-DES) vs. Bare Metal Stent (BMS) and standard uncoated DES (DES) was evaluated on Surface coverage by fibrinogen and platelets and the deposit/aggregate size. Electret-coated DES (e-DES) demonstrated the lowest area of stent surface covered by fibrinogen and platelets and the smallest average size of deposits compared to BMS and standard DES.
Synapse has enriched 10 related papers. Consider them for comparative context: